Ben Hall

Company: 2SeventyBio

Job title: Scientist, Analytical Development

Seminars:

Addressing Safety Assessment in Next Generation Products 9:45 am

• Autologous cellular therapies that incorporate gene editing require safety assays to ensure absence of aberrant transformation in final drug product • These assays include evaluating chromosomal abnormalities, IL-2 independent growth as a surrogate for malignant transformation, and changes resulting from on- or off-target editing • Challenges with these assays such as determining acceptance criteria,…Read more

day: Day Two

Addressing Safety Assessment in Next Generation Products 11:30 am

• Autologous cellular therapies that incorporate gene editing require safety assays to ensure absence of aberrant transformation in final drug product • These assays include evaluating chromosomal abnormalities, IL-2 independent growth as a surrogate for malignant transformation, and changes resulting from on- or off-target editing • Challenges with these assays such as determining acceptance criteria,…Read more

day: Day 2 Track 1 AM